ORIC-533
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
ORIC-533 is a selective, orally bioavailable, small molecule inhibitor of CD73.This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma.
After the RP2D has been determined, dose expansion will further evaluate safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma.
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 1
- Enrollment
- 56 patients (estimated)
- Sponsors
- Oric Pharmaceuticals
- Tags
- CD73 Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1244
- NCT Identifier
- NCT05227144
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.